Historical timeline of breakthrough clinical trials for heart failure... | Download Scientific Diagram
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis | JACC: Heart Failure
Critical Questions about PARADIGM-HF and the Future
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF - ScienceDirect
KoreaMed Synapse
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM
Emerging Mechanisms in the Management of Heart Failure With Reduced Ejection Fraction
Clinical Trial and Biomarker Data | ENTRESTO® (sacubitril/valsartan) | HCP
Frontiers | Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial - Bhatt - 2021 - European Journal of Heart Failure - Wiley Online Library
Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint | Novartis
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review - International Journal of Cardiology
Clinical Trial and Biomarker Data | ENTRESTO® (sacubitril/valsartan) | HCP
Trial Scorecard: PARADIGM-HF
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial - The Lancet Diabetes & Endocrinology
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure | Circulation
Use of Sacubitril/Valsartan in Heart Failure
Promising New Therapies in Heart Failure: Ivabradine and the Neprilysin Inhibitors | USC Journal
PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg. - ppt download
Entresto Use in Heart Failure w Preserved Function – The Early Career Voice
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women - ScienceDirect
Understanding the early mortality benefit observed in the PARADIGM-HF | VHRM
PARADISE MI Trial: Is Sacubitril/valsartan (Entresto) useful in patients with acute MI? – Visualmed
Entrestro for HFrEF: Are there any controversies?
PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF - PACE-CME
